United States · Platforms & data · MarketBeat
What Journey Medical (DERM) Said on Its Q3 Earnings Call
Detailed summary
Journey Medical (NASDAQ:DERM) reported higher third-quarter revenue and a narrower net loss as sales of its rosacea treatment Emrosi grew, while executives said broader insurance coverage could support the product’s pricing and revenue in 2027. The company reported total revenue of $19 million for
MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.marketbeat.com)
